GALECTIN THERAPEUTICS Business Summary

Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company that operates on a pre-revenue business model, generating zero commercial income as of early 2026. The company’s operations are primarily funded through equity offerings and strategic debt financing, including significant credit lines provided by its Chairman. Its primary business segments are focused on the research and development of carbohydrate-based therapies that inhibit the galectin-3 protein to treat fibrotic diseases, oncology, and inflammatory conditions. The company’s lead candidate, belapectin (GR-MD-02), is currently in late-stage clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Within the competitive landscape, Galectin Therapeutics contends with other small-cap biotech firms such as Sagimet Biosciences, BioAge Labs, and Cullinan Therapeutics, positioning itself as a specialist in the niche galectin-3 inhibition space for advanced liver disease. Originally founded in 2000 as Pro-Pharmaceuticals by James C. Czirr and Anatole A. Klyosov, the company is currently led by President and CEO Joel Lewis, a financial executive and CPA with over 25 years of experience, including a tenure as Managing Director at Uline, Inc. The executive team includes Chief Financial Officer Jack Callicutt and Chief Medical Officer Dr. Khurram Jamil, who previously led hepatology drug development at Mallinckrodt. The company’s board and investor profile are notably high-pedigree, featuring Chairman Richard E. Uihlein, the billionaire co-founder of Uline, and prominent directors such as Dr. Benjamin S. Carson, Sr., and Dr. Gilbert F. Amelio, the former CEO of Apple and National Semiconductor. This leadership structure reflects a strategic blend of deep financial backing and specialized medical expertise aimed at navigating the complex FDA approval process for its lead therapeutic programs.